Barclays’s Ensysce Biosciences ENSC Stock Holding History

Barclays’s Portfolio ENSC Stock Details ENSC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$418	Buy	+1,440	New	+$520	﹤0.01%	5035

Other funds holding ENSC

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

TIAM2

Tru Independence Asset Management 2 Portland, Oregon $185M AUM 20.3% 1-Year Est. Return

Barclays's ENSC Position: Q2 2026 in Review

Barclays opened a new position in Ensysce Biosciences (ENSC) in Q2 2026: 1,440 shares worth $418. The stake represents ﹤0.01% of the portfolio and ranks #5035 among its holdings.

18 funds tracked by Wall St. Rank hold ENSC as of Q2 2026.

Barclays held 1,440 shares of Ensysce Biosciences worth $418 as of Q2 2026.
Ensysce Biosciences was a new Barclays position in Q2 2026.
Ensysce Biosciences made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5035 holding.
18 funds tracked by Wall St. Rank held Ensysce Biosciences as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.